Skip to main content
European Commission logo print header

Artificial Intelligence System for Multi-Cancer Detection Support

Project description

A highly accurate diagnostic tool for detecting the earliest stages of cancer

Cancer patient survival is strongly associated with the stage of disease progression at the time of diagnosis. Romanian start-up company Artificial Intelligence Expert (AIE) develops solutions to facilitate the early diagnosis and screening for various types of cancers. AIE focuses on the transition to liquid biopsies, microarray, and next-generation sequencing (NGS) for molecular diagnostics. The technology detects cancer at the earliest stages using circulating microRNAs instead of the currently used circulating tumor DNA or cancer cells. The earliest detection of cancer progression is highly accurate and employs artificial intelligence to analyse microRNA profiles from microarray and NGS data. The EU-funded AI-MICADIS project enables the company to identify partnerships and optimise the best business strategy to bring the technology to the market.

Objective

Need – Each year, over 8M people die of cancer and now the World Health Organization is urging governments to accelerate action to reduce premature mortality. The stage of a cancer progression at the time of diagnosis is strongly associated with patient survival. Unfortunately, the current diagnostic tests and screening tools have very disappointing accuracy rates and many patients remain undiagnosed.

Solution – Artificial Intelligence Expert (AIE) is a Romanian start-up company with a ground-breaking solution that will enable early diagnoses and screening for a wide variety of cancers. AIE aims to leverage the fast transition to liquid biopsies, microarray and next generation sequencing (NGS) for molecular diagnostics. AIE can detect cancer at the earliest stages by using circulating microRNAs instead of the commonly used circulating tumour DNA or circulating cancer cells. AIE is developing an extremely accurate diagnostic tool for detection of the earliest stages of cancer progression using powerful Deep Learning Artificial Intelligence to analyse microRNA profiles from microarray and next generation sequencing (NGS) data.

Market opportunity – The fast increase of big data collection and the associated need to extract knowledge from it drives the AI in healthcare market, which is growing at a CAGR of 53% to $8B by 2022. This market growth is fuelled by a strong growth of the NGS diagnostic market, which is growing at a CAGR of 73%.

Competition – The competition is focusing on optimizing currently used circulating tumour DNA detection tools and simpler machine learning models, that extract a small number of meaningful biomarkers. This keeps the competitor’s data processing needs low, but infringes on the tests’ accuracy and sensitivity.

Feasibility assessment – AIE will use the SMEi phase 1 funding to identify partnerships, perform user involvement study, set out a regulatory path, and optimize the best business strategy to bring the AI-MICADIS to the market.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

ARTIFICIAL INTELLIGENCE EXPERT SRL
Net EU contribution
€ 50 000,00
Address
Strada alexandru vlahuta, bloc lama c, ap.45
400310 Cluj napoca
Romania

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Macroregiunea Unu Nord-Vest Cluj
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00